Horizon offers human disease models and reagents derived from genetically-engineered cells that its customers may use to gain knowledge of the genetic drivers of disease; develop novel drugs or cell therapies targeted at these genetic drivers; and develop companion diagnostics that predict patient response in the clinic.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”.

By editing the code of a patient-derived cell to introduce or repair a genetic change believed to drive disease, a patient’s disease can be reproduced in a laboratory setting, letting researchers ask important biological questions of potential drugs or cell therapies earlier in the drug discovery process.

Horizon now offers over 23,000 cell line pairs that model the mutations found in genetically based diseases.

Once built, engineered cells can act as product manufacturing engines, yielding related cell and reagent products that can be used as research tools or molecular diagnostic reference standards or as a means to generate advanced in vivo models.